Olympus Asia Pacific Innovations Program Finalist Feature - Biocliq
Olympus APAC
Worldwide leading manufacturer of optical and digital precision technology.
We’re on the home straight in our search for a winner in the Olympus Asia Pacific Innovations Program!
Over the past twelve months, Olympus APAC, alongside MedTech Innovator Asia Pacific has been on the search for new and innovative approaches, creating a meaningful role in the advancement of minimally invasive care and new ways to detect, monitor, and treat conditions and diseases. ?The winning innovator will receive grant funding of $75,000 as well as an exclusive mentorship program with key thought leaders from within Olympus.
In the leadup to the winner’s announcement at the Asia Pacific Medical Technology Association (APACMed) Medtech Forum during the 5th and 6th of December, we caught up with the finalists of the Olympus Asia Pacific Innovations Program so that we could learn more about each member, and the groundbreaking technologies they were developing.
Today, we introduce and feature Biocliq. To follow their journey on LinkedIn, click here:
You can find their website here:
A bit about Biocliq:
Biocliq is an AI focused company that is building tech solutions for powering clinical decisions aimed at improving patient care pathways in urology, neurology, cardiology and body fat analysis. Biocliq’s AI Reports unlock insights from medical imaging data, helping doctors accelerate treatment decisions with safer patient outcomes.
Our flagship product is Urologiq - It is the world’s most advanced AI algorithm for powering kidney stone treatment decisions better and faster.
Our AI unlocks insights from CT KUB (Kidney-Ureter-Bladder) scan data and creates a comprehensive report with 3D visuals of kidney stones and key clinical parameters including stone volume, composition, fragility, exact location, access complexity amongst others.
This information enables doctors to decide the most suitable mode of treatment - invasive or noninvasive, and have easier conversations with patients on why a particular mode of surgery will result in a better and safer outcome for the patient.
Urologiq has gone from product development to commercial deployment in 20 months and has been used for over 8000+ patient reports in India.
Over the next 18 months, Urologiq will be available in the North American and South Asian markets and we expect to help at least half a million patients get faster relief from kidney stones.
What disease states do Biocliq specialise in?
Could you share more about the solution that made you a finalist for the Olympus Asia Pacific Innovation program?
What’s the first thing that comes to your mind when you hear kidney stones?
领英推荐
‘Drink more water and they will pass’.
If you or a family member who experienced the second most painful experience known to humankind AKA ‘kidney stones stuck in your ureter’, you might disagree.
Kidney stones affect about 1 in 10 adults and the current method of diagnosis results in more ‘time-in-pain’ for patients.
As a patient, you only see a small white dot on a black and white film and medicolegalese in the Radiologist’s report. Anxiety increases further if surgery is required, and often treatments can be delayed as one tries to look for non invasive treatment options.
Our flagship product Urologiq changes ‘The Kidney Stone Experience’ for both doctors and patients. Urologiq is generated with 5 minutes after a CT scan and available for doctor’s review in the cloud.
Actionable clinical insights from the report help doctors decide on an optimal treatment plan.
Vivid and intricate 3D visualization of the Stones along with the Kidney - Ureter and bladder system help patients understand exactly, what type of surgery is required - and why!
Surgeries can be planned with accuracy and surgery times can be reduced by up to 40%. This reduces the morbidity for patients, increases Stone Free Rates, reduces radiation for both patient and doctors and improves patient outcomes.
More information is available at our website https://www.biocliq.ai/
What does the perfect future look like for Biocliq?
We believe the medical imaging space will see massive improvement in the quality of reports and access to clinical insights that will be unlocked via increasingly sophisticated deep learning algorithms.
Biocliq wants to lead the way in empowering physicians and surgeons globally by making accessible, previously unavailable insights from medical imaging data. We want to be leaders in AI-aided Preoperative surgical planning to ensure minimally invasive procedures for urology.
Over the next 5 to 10 years, we see Biocliq's reports becoming the gold standard for advanced medical imaging reporting in neurology, cardiology and eventually expanding to all areas of the human body that could benefit from advanced insights generated by our AI algorithms.
What opportunities Biocliq sees in potentially winning the Olympus Asia Pacific Innovation Program?
Olympus is a global medical technology company and a leader in using its innovative capabilities to to deliver advanced diagnostic and minimally invasive procedures to healthcare professionals.
Winning the program will recognise Biocliq’s capabilities and efforts over the last 4+ years, in developing AI technology for advanced diagnostics that improve patient treatment pathways.
We foresee our surgical planning reports complimenting Olympus’s hardware and software products, and look to forming a partnership that could enable teams in 40+ countries to experience AI led innovation in diagnostics and surgery planning.